UPDATE: Brookline Capital Markets Starts FSD Pharma Inc (HUGE) at Buy

August 20, 2020 1:51 PM EDT
Get Alerts HUGE Hot Sheet
Price: $1.55 -4.32%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - August 20, 2020 1:56 PM EDT)

(Updated to add analyst comment)

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on FSD Pharma Inc (NASDAQ: HUGE) with a Buy rating and a price target of $11.00.

Analyst says: "We are initiating on FSD Pharma with a Buy rating and a Price Target of $11 based on potential of FSD201 in treating COVID-19. FSD201 could also be potentially developed for osteoarthritis of knee, endometriosis, and chronic pain. It has a novel mechanism of action by stimulating the CB2 receptor. FSD201 has potential in other disease
areas like pain where endocannabinoid system has been shown to play a role. We see a favorable risk-reward proposition as the pipeline advances."

For an analyst ratings summary and ratings history on FSD Pharma Inc click here. For more ratings news on FSD Pharma Inc click here.

Shares of FSD Pharma Inc closed at $2.76 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage